Mark Moasser

Mark Moasser

UNVERIFIED PROFILE

Are you Mark Moasser?   Register this Author

Register author
Mark Moasser

Mark Moasser

Publications by authors named "Mark Moasser"

Are you Mark Moasser?   Register this Author

49Publications

753Reads

7Profile Views

A Dimerization Function in the Intrinsically Disordered N-Terminal Region of Src.

Cell Rep 2018 10;25(2):449-463.e4

Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2018.09.035DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226010PMC
October 2018

HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3.

Cancer Res 2018 07 14;78(13):3645-3658. Epub 2018 May 14.

Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-18-0430DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6779043PMC
July 2018

Targeting HER2 by Combination Therapies.

J Clin Oncol 2018 03 30;36(8):808-811. Epub 2018 Jan 30.

Ana Ruiz-Saenz, University of California at San Francisco, San Francisco, CA; and Mark M. Moasser, University of California at San Francisco, San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.1899DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6053674PMC
March 2018

CD318 is a ligand for CD6.

Proc Natl Acad Sci U S A 2017 08 31;114(33):E6912-E6921. Epub 2017 Jul 31.

Department of Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195;

View Article

Download full-text PDF

Source
http://www.pnas.org/lookup/doi/10.1073/pnas.1704008114
Publisher Site
http://dx.doi.org/10.1073/pnas.1704008114DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565428PMC
August 2017

Disentangling multidimensional spatio-temporal data into their common and aberrant responses.

PLoS One 2015 22;10(4):e0121607. Epub 2015 Apr 22.

Department of Electrical Engineering and Computer Sciences, University of California, Berkeley, CA, USA; Faculty Scientist, Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0121607PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4406848PMC
April 2016

Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin.

Breast Cancer Res Treat 2016 Feb 9;155(3):431-40. Epub 2016 Feb 9.

Radiation Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, UCSF Box 1708, San Francisco, CA, 94143, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-016-3698-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4767608PMC
February 2016

A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.

Breast Cancer Res Treat 2016 Feb 13;155(3):521-30. Epub 2016 Feb 13.

Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, Box 1710, San Francisco, CA, 94115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-016-3701-7DOI Listing
February 2016

A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers.

Mol Cancer Ther 2015 Dec 5;14(12):2805-17. Epub 2015 Oct 5.

Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-15-0403DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674361PMC
December 2015

Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib.

Oncotarget 2015 Dec;6(38):41123-33

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.5660DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747394PMC
December 2015

The Evolving Landscape of HER2 Targeting in Breast Cancer.

JAMA Oncol 2015 Nov;1(8):1154-61

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.2286DOI Listing
November 2015

HER Targeting in HER2-Negative Breast Cancers: Looking for the HER3 Positive.

Clin Cancer Res 2015 Jul 21;21(13):2886-8. Epub 2015 Jan 21.

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-3012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490014PMC
July 2015

Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology.

J Clin Oncol 2015 Mar 20;33(7):786-809. Epub 2015 Jan 20.

Gregory Masters, Helen F. Graham Cancer Center, Newark, DE; Lada Krilov and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Howard H. Bailey, University of Wisconsin Hospital and Clinics, Madison, WI; Marcia S. Brose, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Harold Burstein and Lisa R. Diller, Dana-Farber Cancer Institute; Don S. Dizon, Massachusetts General Hospital, Boston, MA; Howard A. Fine, New York University Langone Medical Center; Gary K. Schwartz, Columbia University Medical Center, New York, NY; Gregory P. Kalemkerian, University of Michigan Health System; Sandra L. Wong, University of Michigan, Ann Arbor, MI; Mark Moasser, University of California San Francisco School of Medicine; Charles J. Ryan and Alan P. Venook, University of California San Francisco, San Francisco; Steven J. O'Day, Beverly Hills Health Center, Beverly Hills, CA; Michael N. Neuss, Vanderbilt-Ingram Cancer Center, Nashville, TN; Olatoyosi Odenike, University of Chicago; and Jyoti D. Patel, Northwestern University, Chicago, IL.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/01/16/JCO.2014.59
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.59.9746
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.59.9746DOI Listing
March 2015

A multilevel model of postmenopausal breast cancer incidence.

Cancer Epidemiol Biomarkers Prev 2014 Oct 13;23(10):2078-92. Epub 2014 Jul 13.

Department of Medicine, Stanford University, Stanford, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-14-0403DOI Listing
October 2014

Two dimensions in targeting HER2.

Authors:
Mark M Moasser

J Clin Oncol 2014 Jul 27;32(19):2074-7. Epub 2014 May 27.

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.55.7652DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517047PMC
July 2014

Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.

J Clin Oncol 2014 May 7;32(14):1472-9. Epub 2014 Apr 7.

A. Jo Chien, Pamela N. Munster, Michelle E. Melisko, Hope S. Rugo, John W. Park, Andrei Goga, Glenna Auerback, Elham Khanafshar, and Mark M. Moasser, Helen Diller Family Comprehensive Cancer Center; A. Jo Chien, Pamela N. Munster, Michelle E. Melisko, Hope S. Rugo, John W. Park, Andrei Goga, Glenna Auerback, Elham Khanafshar, Karen Ordovas, and Mark M. Moasser, University of California San Francisco, San Francisco, CA; and Kevin M. Koch, GlaxoSmithKline, Research Triangle Park, NC.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2014/04/09/JCO.2013.52
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2013.52.1161
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.52.1161DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017711PMC
May 2014

RETRACTED: An ATP-competitive inhibitor modulates the allosteric function of the HER3 pseudokinase.

Chem Biol 2014 04 20;21(4):453-458. Epub 2014 Mar 20.

Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA 94158, USA; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.chembiol.2014.02.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018233PMC
April 2014

Trask loss enhances tumorigenic growth by liberating integrin signaling and growth factor receptor cross-talk in unanchored cells.

Cancer Res 2013 Feb 12;73(3):1168-79. Epub 2012 Dec 12.

Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-12-2496DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563920PMC
February 2013

HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells.

Biochem J 2012 Nov;447(3):417-25

Department of Medicine and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1042/BJ20120724DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3722874PMC
November 2012

Trask phosphorylation defines the reverse mode of a phosphotyrosine signaling switch that underlies cell anchorage state.

Cell Cycle 2011 Apr 15;10(8):1225-32. Epub 2011 Apr 15.

Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3117134PMC
http://dx.doi.org/10.4161/cc.10.8.15343DOI Listing
April 2011

The structural features of Trask that mediate its anti-adhesive functions.

PLoS One 2011 Apr 29;6(4):e19154. Epub 2011 Apr 29.

Department of Medicine, University of California San Francisco, San Francisco, California, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0019154PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3084758PMC
April 2011

The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.

Semin Cell Dev Biol 2010 Dec 9;21(9):944-50. Epub 2010 Sep 9.

University of California, San Francisco, Medicine, San Francisco, CA 94143-1387, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semcdb.2010.08.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2991618PMC
December 2010

HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.

Clin Cancer Res 2010 Mar 23;16(5):1373-83. Epub 2010 Feb 23.

Department of Medicine & Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California 94143-1387, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-1218DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831167PMC
March 2010

The transmembrane src substrate Trask is an epithelial protein that signals during anchorage deprivation.

Am J Pathol 2009 May 6;174(5):1756-65. Epub 2009 Apr 6.

Department of Medicine, University of California, San Francisco, San Francisco, California 94143-0875, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S000294401061033
Publisher Site
http://dx.doi.org/10.2353/ajpath.2009.080890DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2671264PMC
May 2009

HER-2-directed, small-molecule antagonists.

Curr Opin Investig Drugs 2008 Dec;9(12):1264-76

Department of Medicine and Comprehensive Cancer Center, Box 0875, San Francisco, CA 94143-0875, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031872PMC
December 2008

Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired.

Semin Oncol 2008 Apr;35(2 Suppl 2):S1-S14; quiz S39

Department of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2008.02.010DOI Listing
April 2008

Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy.

J Magn Reson Imaging 2007 Dec;26(6):1618-25

Department of Medicine, University of California, San Francisco, San Francisco, California 94143, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jmri.21196DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024590PMC
December 2007

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.

Nature 2007 Jan 7;445(7126):437-41. Epub 2007 Jan 7.

Department of Medicine, University of California, San Francisco 94143, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature05474DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3025857PMC
January 2007

Adhesion signaling by a novel mitotic substrate of src kinases.

Oncogene 2005 Aug;24(34):5333-43

School of Medicine, University of California, San Francisco, CA 94143, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/1208582
Publisher Site
http://dx.doi.org/10.1038/sj.onc.1208582DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023961PMC
August 2005

S-phase inhibition of cell cycle progression by a novel class of pyridopyrimidine tyrosine kinase inhibitors.

Cell Cycle 2004 Jun 5;3(6):796-803. Epub 2004 Jun 5.

Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

View Article

Download full-text PDF

Source
June 2004

Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.

Clin Cancer Res 2003 Oct;9(12):4340-6

Department of Medicine and Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
October 2003

A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants.

Clin Cancer Res 2003 Apr;9(4):1267-73

Department of Medicine, Memorial Sloan-Kettering Cancer Center and Program in Pharmacology, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
April 2003